linjc16/ctgov huggingface dataset:
Transcranial Magnetic Stimulation (TMS) for CRPS

Study Overview
=================
Brief Summary
-----------------
The purpose of this pilot study is to test the durability of response to Transcranial Magnetic Stimulation (TMS) for the symptoms of Complex Regional Pain Syndrome (CRPS). The investigators will test various methods of TMS for varying lengths of time in a pilot study to investigate what the clinical impact.

Official Title
-----------------
Transcranial Magnetic Stimulation for CRPS

Conditions
-----------------
Complex Regional Pain Syndrome (CRPS)

Intervention / Treatment
-----------------
* Device: Transcranial Magnetic Stimulation (TMS)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 or older Diagnosis of CRPS (complex regional pain syndrome) Average pain level reported on Numerical Rating Scale meets entry criteria Ability to perform the experimental task and procedures. Exclusion Criteria: MRI contraindication (metal implants or devices, claustrophobia) TMS Contraindication (eg metal implant or devices near the site of stimulation) History of epilepsy History of a psychological or psychiatric disorder that would interfere with study procedures, at the discretion of the researcher. Neurologic illness that would interfere with brain integrity Current medical condition or medication use that would interfere with study procedures or data integrity, at the discretion of the researcher. Currently pregnant or planning to become pregnant. On going legal action or disability claim.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: TMS Intervention for 5 days<br>Application of Transcranial Magnetic Stimulation (TMS) for up to 5 days | Device: Transcranial Magnetic Stimulation (TMS)<br> <br> |
| Experimental: TMS Intervention for 1 day<br>Application of Transcranial Magnetic Stimulation (TMS) for 1 day | Device: Transcranial Magnetic Stimulation (TMS)<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Present Pain Intensity | Present pain intensity was reported by participants using a visual analog scale (VAS) from scores ranging from 1-10; lower scores represent less pain, higher scores represent more severe pain. | Baseline, post-treatment, one week follow-up |
High-Shear Microfluidic Thrombosis Assay

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to characterize a new test to assess the rate and time it takes to form a blood clot in people who either do or do not take aspirin.

Detailed Description
-----------------
It is estimated that approximately 25% of people are resistant to aspirin, or do not respond to its effect. These individuals have a four fold higher risk of a heart attack or stroke compared to those who respond to aspirin. Current tests for determining those who are aspirin resistant are not reliable. This study is assessing the effectiveness of a new assay in determining the rate and time it takes for people who are or are not on aspirin in forming a blood clot.

Official Title
-----------------
Characterization of a Novel High-Shear Thrombosis Assay in Normal and Aspirin-treated Patients

Conditions
-----------------
Coagulation Defects, Other and Unspecified

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria for no aspirin group: have not taken aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs), or clopidogrel in the previous 10 days no history of myocardial infarction, ischemic stroke, or other ischemic event Inclusion Criteria for aspirin daily group: have taken aspirin daily over the last 10 days or more no history of myocardial infarction, ischemic stroke, or other ischemic event Inclusion Criteria for new to aspirin group: have not previously been prescribed aspirin, but have been prescribed aspirin at their present appointment, e.g. a high calcium plaque score on CT no history of myocardial infarction, ischemic stroke, or other ischemic event Exclusion Criteria: a known bleeding or thrombotic disorder Exclusion Criteria for new to aspirin group: a known bleeding or thrombotic disorder have taken aspirin, other NSAIDs, clopidogrel, or an anticoagulant in the previous 10 days

Ages Eligible for Study
-----------------
Minimum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No aspirin<br>Subjects who have not taken aspirin or other blood thinners in the previous 10 days | |
| Aspirin Daily<br>Subjects who have taken aspirin daily for the previous 10 or more days | |
| New to aspirin<br>Subjects newly started on aspirin during their visit | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Thrombotic occlusion time | A microfluidic assay will be used to assess thrombus formation induced by exposed collagen within a stenosis that induces high shear rates. The amount of time taken to completely occlude an aperture is called the thrombotic occlusion time. | 30 minutes |
Safety and Immunogenicity of Meningococcal Conjugate Vaccine in Healthy Adults Aged 19 to 55 Years Old

Study Overview
=================
Brief Summary
-----------------
Phase I study to evaluate safety and immunogenicity in healthy adult subjects following a single dose administration of Meningococcal (Group A, C, W-135, and Y)-CRM197 Conjugate vaccine

Official Title
-----------------
A Single Center, Randomized, Observer-blinded, Active Comparator Phase I Study to Assess the Safety and Immunogenicity of Meningococcal (Groups A, C, W-135 and Y) Conjugate Vaccine in Healthy Adults Aged 19 to 55 Years Old

Conditions
-----------------
Infection, Meningococcal

Intervention / Treatment
-----------------
* Biological: Meningococcal(Groups A, C, W-135, and Y) Conjugate Vaccine
* Biological: Meningococcal(Groups A, C, Y, and W-135) Conjugate Vaccine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects 19 to 55 years of age Written informed consent Available for all visits and telephone calls scheduled for the study Exclusion Criteria: Previous or suspected disease caused by N. meningitidis Household and/or intimate exposure to an individual with culture-proven N. meinigitidis infection within 60 days prior to screening Serious acute, chronic or progressive disease as determined by investigator History of alcohol or substance abuse

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: EuMCV4<br>Healthy adults received 0.5mL single intramuscular dose on Day 0. | Biological: Meningococcal(Groups A, C, W-135, and Y) Conjugate Vaccine<br>* 0.5mL single intramuscular dose on Day 0<br>* Other names: EuMCV4;|
| Active Comparator: Menveo<br>Healthy adults received 0.5mL single intramuscular dose on Day 0. | Biological: Meningococcal(Groups A, C, Y, and W-135) Conjugate Vaccine<br>* 0.5mL single intramuscular dose on Day 0<br>* Other names: Menveo;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Occurrence of solicited adverse events | local and systemic AEs | within 7 days post vaccination | 
| Occurrence of unsolicited adverse events |  | within 28 days post vaccination | 
| Occurrence of serious adverse events |  | within 180 days post vaccination |
Regulation of Intraarticular and Synovium-related Biomarkers of Osteoarthritis. Effect of Acute Mechanical Joint Loading

Study Overview
=================
Brief Summary
-----------------
In the present study the microdialysis method is used to investigate biochemical changes within and around the joint simultaneously in both the resting state and in a joint that had been subjected to exercise. The aim of the present study was, by applying the microdialysis technique, to monitor markers of cartilage breakdown and inflammation in 2 different positions of the knee (inside and in the inner part of the knee capsule) in a group of human females with knee osteoarthritis over a period of 3 hours.

Conditions
-----------------
Osteoarthritis, Exercise

Intervention / Treatment
-----------------
* Other: Exercise
* Other: Non Exercise


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: verified osteoarthritis (x-ray)of the knee, female, Exclusion Criteria: dementia, inflammatory diseases, regular pain medication

Ages Eligible for Study
-----------------
Minimum Age: 55 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Parallel Assignment


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Exercise<br> | Other: Exercise<br> <br> |
| Placebo Comparator: Non Exercise<br> | Other: Non Exercise<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
osteoarthritis, biochemical markers, cartilage, inflammation, microdialysis
Comparison of Laryngeal Masks in Urethral Cystoscopic Surgery Operations: a Prospective Randomized Clinical Study

Study Overview
=================
Brief Summary
-----------------
The use of Laryngeal masks are increased.This study aimed to compare lma pro seal and baska -mask in urethral retrograde sistoscopy operations.

Detailed Description
-----------------
The use of Laryngeal masks are increased. Aimed to compare lma pro seal and baska -mask in urologic retrograde sistoscopy operations. ASA 1-2 80 subjects who is undergoing elective URS operations were enrolled in this prospective randomized clinical study. The demographic and airway characteristics of patients preoperatively and lam insertion times, nasogastric insertion times number of intubation attempts, fiberoptic grades from the lam, expired tidal volume, oropharyngeal leak pressures, peak and mean airway pressures preoperatively, minor complications like sore throat, hoarseness, dysphagia were recorded at the postoperative care unit.

Official Title
-----------------
Comparison of Pro Seal and Baska-mask

Conditions
-----------------
Ureteral Calculi

Intervention / Treatment
-----------------
* Device: proseal
* Device: baska-mask


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:18-65 years of age undergoing elective urs operations bmı<35 ASA I-II Exclusion Criteria:<18 years of age bmı>35 ASA III-IV

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: insertion time<br>lma pro seal and basks-mask in patients undergoing ups | Device: proseal<br>* laryngeal mask proseal<br>* Other names: laryngeal mask;Device: baska-mask<br>* laryngeal mask baska-mask<br>* Other names: laryngeal mask;|
| Active Comparator: oropharyngeal leak pressure<br>lma baska-mask undergoing urs | Device: proseal<br>* laryngeal mask proseal<br>* Other names: laryngeal mask;Device: baska-mask<br>* laryngeal mask baska-mask<br>* Other names: laryngeal mask;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| insertion time | insertion time of the laryngeal mask | 20 seconds | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
baska-mask, proseal, urs
Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes

Study Overview
=================
Brief Summary
-----------------
This trial is conducted in the United States of America (USA). The purpose of this study is to determine if the use of insulin detemir in combination with insulin aspart is safe and at least as effective as insulin glargine in combination with insulin aspart for the control of blood glucose in patients with Type 2 diabetes.

Official Title
-----------------
Efficacy and Safety Comparison of Insulin Detemir and Insulin Glargine Plus Insulin Aspart in Patients With Type 2 Diabetes

Conditions
-----------------
Diabetes, Diabetes Mellitus, Type 2

Intervention / Treatment
-----------------
* Drug: insulin detemir
* Drug: insulin glargine
* Drug: insulin aspart


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Type 2 Diabetes for more than 12 months Currently treated with glucose lowering tablets or insulin HbA1c: 7.0-12.0%

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: insulin detemir|nan|
|Drug: insulin glargine|nan|
|Drug: insulin aspart|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HbA1c |  | after 26 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Body weight |  |  | 
| Glucose profiles |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Diabetes, Type 2
Analyzing Patient Flows at the Emergency Department by Data Analytics, Simulation, and Optimization

Study Overview
=================
Brief Summary
-----------------
In this project, investigators apply operations research techniques, more specifically data analytics, system simulation, mathematical modelling, and optimization, for analyzing and improving operations in the Emergency Department at the Prince of Wales Hospital. The long term goals of this project are to demonstrate that integrated approach of data analytics and systems thinking is beneficial to health service planning and to extend present work to applications in other health-service systems.

Detailed Description
-----------------
Design and subjects The current study requires time stamps for which patients start and end activities in the department. Personally identifiable information is not needed in this study. Investigators will collect the data from the computer system of the Department. The data will be used for data analysis and the development of simulation and optimization models. With current models, investigators investigate the effects of queueing policies, study workforce planning, and conduct a cost-effectiveness analysis for strategic planning. Study instruments Data analytics tools and simulation and optimization softwares are needed in this research. Interventions With simulation and optimization models, investigators examine the impacts of different operational strategies on the performance of the Emergency Department. The Computational experiments will not disturb the actual operations but will provide insights into the effectiveness of the various intervention policies. Main Outcome Measures Investigators will derive insights from computational experiments and deliver useful recommendations for managing emergency department operations in Hong Kong.

Official Title
-----------------
Analyzing Patient Flows at the Emergency Department by Data Analytics, Simulation, and Optimization

Conditions
-----------------
Emergency Patients

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All the patients attended to the Emergency Department of Prince of Wales Hospital in the period of July 2017 to June 2018 will be included in this study. Exclusion Criteria: No patient will be excluded in this study
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quantitative models | Quantitative models, powered by domain knowledge of the Emergency Department (ED) system and ED operational data, will be developed to address three main operational problems in an ED: patient waiting time prediction, impacts of an adoption of a fast-track system, and patient scheduling | 12 months after recruitment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Emergency department, Simulation, Patient Flows
T-wave Alternans and Intrathoracic Impedance Measurements

Study Overview
=================
Brief Summary
-----------------
T-wave alternans is a test that is currently being used to risk stratify patients with structural heart disease for sudden cardiac death. The mechanism of T-wave alternans is unclear, but may share a common abnormality with conditions of cardiac fluid overload such as heart failure, which is altered intracellular calcium handling. Current Medtronic implantable defibrillators have the capability of monitoring cardiac fluid status via transthoracic impedance measurements. The purpose of this study is to determine if a correlation exists between T-wave alternans status and cardiac volume status, as determined by transthoracic impedance measurements. Secondarily, the study seeks to examine the relationship between arrhythmia frequency and T-wave alternans or cardiac volume status.

Official Title
-----------------
T-wave Alternans and Intrathoracic Impedance Measurements

Conditions
-----------------
Congestive Heart Failure, Arrhythmias

Intervention / Treatment
-----------------
* Other: Congestive heart failure


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Class III or IV heart failure patients with a chronically implanted Medtronic biventricular defibrillator system capable of monitoring intrathoracic fluid volume. Exclusion Criteria: no active ischemia or pulmonary edema, atrial fibrillation, complete heart block

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group A<br>The study group will include Class III to IV heart failure patients followed in the device clinic that have a chronically implanted (more than 90 days) Medtronic biventricular defibrillator with the ability to monitor intrathoracic impedance. | Other: Congestive heart failure<br>* Spontaneous occurrence of fluid overload.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Positive Twave Studies and Concurrent Positive Optivol Measurement | We wanted to examine whether positive Optivol status corresponded to a higher likelihood of a positive T wave study. The T wave alternans result is determined by a proprietary device that measures T wave and reports the result as negative, positive, or indeterminate. The Optivol measurement is obtained through transthoracic impedance values in the implanted device. We investigated the correlation between Optivol status and T wave alternans status. | upto 3 years |
Evaluation of Body-worn Multimodal Hand Hygiene System. Impact on Health-Care Associated Infections

Study Overview
=================
Brief Summary
-----------------
Evaluate the efficacy of a multimodal hand hygiene system in the intensive care unit environment and evaluate any impact on health care associated infections.

Detailed Description
-----------------
Deploy and utilize a novel body worn hand hygiene system that incorporates provider and group specific feedback allowing hand hygiene to occur directly within the patient environment. We hypothesize that by improving provider hand hygiene we will reduce health-care associated infection rates.

Official Title
-----------------
Real Time Deployment of Multimodal Personal Dispenser Hand Hygiene System in a Multidisciplinary Intensive Care Unit.

Conditions
-----------------
Nosocomial Infection

Intervention / Treatment
-----------------
* Device: Body worn alcohol gel dispenser
* Drug: 62% ethanol based hand cleanser
* Behavioral: Educational component with regard to teaching CDC guidelines
* Behavioral: Provider and group feedback


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All ICU patients Exclusion Criteria: Patient is not in an ICU at our Institution
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Sprixx Device Group<br>Treatment group utilizing multimodal hand hygiene device | Device: Body worn alcohol gel dispenser<br>* Records hand hygiene events of provider and tabulates on the group level.<br>Drug: 62% ethanol based hand cleanser<br>* CDC based guidelines with regard to utilization in the health care environment the nest<br>Behavioral: Educational component with regard to teaching CDC guidelines<br>* 12 minute education prior to deploying device for all providers.<br>Behavioral: Provider and group feedback<br>* Provide feedback with regard to expected hand hygiene goals to providers and reported anonymous group results based on recorded information.<br>|
| Standard Hand Hygiene Group<br>Utilizing wall mounted dispensers and CDC based guidelines. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reduction in healthcare associated infections (CRBSI and VAP) |  | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to infections Hospital mortality Length of stay |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Alcohol Rub, Hand Hygiene, Provider Feedback, Health Care Associated Infections